Reuters logo
BRIEF-Novo Nordisk: Novelion CEO leaves board to avoid potential conflict of interest
May 16, 2017 / 2:26 PM / 4 months ago

BRIEF-Novo Nordisk: Novelion CEO leaves board to avoid potential conflict of interest

May 16 (Reuters) - Novo Nordisk:

* Says Mary Szela steps down from Novo Nordisk’s board of directors with immediate effect

* “The decision follows changed strategic focus for Novelion Therapeutics, a US-based rare disease company, where Ms Szela serves as CEO, which could lead to a potential conflict of interest” Source text for Eikon: Further company coverage: (Reporting by Stine Jacobsen)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below